Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - June 2013




Expertise in Neuropharmacology






Summer News

Higher Doctorate awarded by University of Kent

Dr. Adrian Newman-Tancredi PhD has been awarded a DSc (“Higher Doctorate”) by the University of Kent at Canterbury in recognition of his work in neuropharmacology.
Dr. Newman-Tancredi had submitted a thesis summarizing the research work he has carried out over two decades since gaining his PhD from the same University.

Conference presentation

Dr Newman-Tancredi gave a lecture on 27th May at the Dopamine 2013 meeting in Alghero, Sardinia. The congress was attended by over 300 researchers specializing in the study of systems controling disorders including psychosis, parkinson's disease and addiction.

University lectures

Adrian has recently given a series of lectures at institutions in the United States (Columbia University, New York and University of Texas Health Science Center at San Antonio; February 2013) and in the Netherlands (Utrecht University; March 2013). The lectures focused on novel pharmacotherapeutic treatments for depressive disorders and schizophrenia.

For more information on Adrian's lectures and neuropharmacology expertise: Consulting services.












Adrian Newman-Tancredi is co-founder and Chief Scientific Officer of Neurolixis Inc., a CNS drug discovery and development start-up. Neurolixis is advancing its program of in-licensing clinical assets and synthesis of Novel Chemical Entities.

Neurolixis is currently aquiring financing from investors and grant-awarding institutions to support its drug discovery and early development projects. For further information or to make an investment, Contact.


Free Online Webinar on neuropsychiatric drug discovery

Adrian Newman-Tancredi will give a free online webinar on 20th June on drug discovery of new therapeutics targeted at BPSD (Behavioral and Psychological Symptoms of Dementia). BPSD is a substantial unmet need in the context of the increasing prevalence of dementia due to ageing populations.

For further information click here.



Scientific Communication

Just Published:

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

Auclair AL, Martel JC, Assié MB, Bardin L, Heusler, P, Cussac D, Marien M, Newman-Tancredi A, O'Connor J, Depoortère R. 
Neuropharmacology. 2013 Jul; 70:338-47.

The publication shows that levomilnacipran has accentuated noradrenergic vs serotonergic activity, unlike the other SNRIs, duloxetine and venlafaxine. The distinctive activity of levomilnacipran may translate to a different therapeutic profile in clinical use. Levomilnacipran was developed in the USA by Forest laboratories and is awaiting FDA approval.



NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.  

 NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi PhD DSc, an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile